{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:38:17Z","timestamp":1787985497272,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-vascular endothelial growth factor (Anti-VEGF) therapy is now considered as one of standard therapies in approaching infants with retinopathy of prematurity (ROP). The purpose of this study was to assess the time to full retinal vascularization in infants with ROP who were treated with intravitreal bevacizumab (IVB).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study evaluated premature infants with ROP who were treated with IVB between 2012 and 2019. Demographic and clinical data were collected from the medical records and analyzed. Main outcomes were defined as time to complete vascularization and time of zone shift.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight hundred sixty-five eyes from 441 patients were included. Average gestational age and birth weight were 28\u2009\u00b1\u20094\u00a0weeks and 1121\u2009\u00b1\u2009624\u00a0g, respectively. Primary treatment failure and reactivation occurred in 35 eyes (4.0%) and 33 eyes (3.8%), respectively. Recurrent ROP occurred significantly more frequently in infants with pre-treatment zone 1 ROP compared to those with zone 2 ROP (7.6% versus 3%, p\u2009&lt;\u20090.01). Patients with pre-treatment zone 2 reached zone 3 faster than those with pre-treatment zone 1 (142\u2009\u00b1\u2009152\u00a0days versus 181\u2009\u00b1\u2009174\u00a0days, p\u2009&lt;\u20090.01); however, the time until full retinal vascularization did not significantly differ between the groups (p\u2009=\u20090.10).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study revealed that pre-treatment ROP zone was associated with ROP reactivation rate but not with time to full vascularization in those treated with IVB.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Retrospectively registered; IR.TUMS.FARABI.REC.1399.040<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-022-00364-6","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T13:03:20Z","timestamp":1645621400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity"],"prefix":"10.1186","volume":"8","author":[{"given":"Masoud","family":"Mirghorbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Rashidinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Yaseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Khojasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-2028","authenticated-orcid":false,"given":"Fatemeh","family":"Bazvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobeck S.","family":"Modjtahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"issue":"7","key":"364_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3928\/23258160-20170630-06","volume":"48","author":"CA Ludwig","year":"2017","unstructured":"Ludwig CA, Chen TA, Hernandez-Boussard T, Moshfeghi AA, Moshfeghi DM. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48(7):553\u201362.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"364_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","volume":"122","author":"ME Hartnett","year":"2015","unstructured":"Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122(1):200\u201310.","journal-title":"Ophthalmology"},{"issue":"26","key":"364_CR3","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and Management of Retinopathy of Prematurity. N Engl J Med. 2012;367(26):2515\u201326.","journal-title":"N Engl J Med"},{"key":"364_CR4","doi-asserted-by":"crossref","unstructured":"Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G. The Early Treatment for Retinopathy Of Prematurity Study: structural findings at age 2 years. Br J Ophthalmol. 2006;90 (11):1378\u20131382.","DOI":"10.1136\/bjo.2006.098582"},{"issue":"1","key":"364_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","volume":"18","author":"Z Li","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018;18(1):19.","journal-title":"BMC Ophthalmol"},{"issue":"7","key":"364_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"364_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ajo.2010.10.007","volume":"151","author":"S Jalali","year":"2011","unstructured":"Jalali S, Kesarwani S, Hussain A. Outcomes of a protocol-based management for zone 1 retinopathy of prematurity: the Indian twin cities ROP Screening Program Report Number 2. Am J Ophthalmol. 2011;151(4):719-724.e712.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"364_CR8","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1111\/aos.13008","volume":"94","author":"R Karkhaneh","year":"2016","unstructured":"Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol. 2016;94(6):e417\u201320.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"364_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/0301-4738.128639","volume":"62","author":"G Sanghi","year":"2014","unstructured":"Sanghi G, Dogra M, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity in infants & 1500 g birth weight. Indian J Ophthalmol. 2014;62(2):254\u20137.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"364_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122(5):1008\u201315.","journal-title":"Ophthalmology"},{"issue":"9","key":"364_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor R, Karkhaneh R, Riazi-Esfahani M, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmology Retina. 2018;2(9):942\u20138.","journal-title":"Ophthalmology Retina"},{"issue":"9","key":"364_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","volume":"40","author":"KP Ling","year":"2020","unstructured":"Ling KP, Liao PJ, Wang NK, et al. Rates and risk factors for reactivation of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy. Retina. 2020;40(9):1793\u2013803.","journal-title":"Retina"},{"key":"364_CR13","doi-asserted-by":"publisher","first-page":"2721578","DOI":"10.1155\/2019\/2721578","volume":"2019","author":"AM Solans P\u00e9rez de Larraya","year":"2019","unstructured":"Solans P\u00e9rez de Larraya AM, Ortega Molina JM, Uberos Fern\u00e1ndez J, Gonz\u00e1lez Ram\u00edrez AR, Garc\u00eda Serrano JL. Speed of retinal vascularization in retinopathy of prematurity: risk and protective factors. BioMed Res Int. 2019;2019:2721578.","journal-title":"BioMed Res Int"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-022-00364-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-022-00364-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T13:33:16Z","timestamp":1645623196000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-022-00364-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s40942-022-00364-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The infants\u2019 parents or legal guardians provided written informed consent.Please refer to methods section. ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consents were obtained from infants\u2019 parents or legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}